Biological seed treatments using nematophagous fungi for soybean SDS mitigation
This innovative solution employs nematophagous fungi as biological seed treatments to mitigate Sudden Death Syndrome (SDS) in soybeans. By reducing soybean cyst nematode (SCN) populations and inhibiting Fusarium virguliforme, it provides a sustainable alternative to chemical treatments.
Overview
Biological seed treatments with nematophagous fungi offer a groundbreaking approach to combat Sudden Death Syndrome (SDS) in soybeans. This method leverages the natural capabilities of fungi such as Arthrobotrys, Duddingtonia, and Pochonia to reduce populations of soybean cyst nematodes (SCN) and inhibit the pathogen Fusarium virguliforme. By applying these fungi as seed inoculants, farmers can achieve dual-action protection, enhancing yield and sustainability by decreasing reliance on chemical nematicides and fungicides.
Technical specifications
- Nematophagous Fungi: These fungi trap and parasitize nematodes, reducing SCN populations and indirectly lowering SDS severity.
- Candidate Species: Includes Arthrobotrys, Duddingtonia, and Pochonia, tested for nematicidal activity, root colonization, and antagonism against Fusarium.
- Application Method: Fungi are formulated as spore suspensions or granules for seed application, integrating seamlessly into existing seed treatment pipelines.
- Validation: Initial assays have shown SCN suppression and varied fluopyram sensitivity. Future work involves soil microcosm validation, greenhouse experiments, and pilot coating trials to ensure efficacy and compatibility with commercial fungicides.
Technology readiness level
Currently at TRL 2, this technology is in the early stages of development, having shown promising results in preliminary assays. Ongoing efforts aim to validate nematophagous activity in microcosms and greenhouse settings, with plans for pilot trials and regulatory consideration for commercial scale-up.
About The Ohio State University
The Ohio State University is a comprehensive public land‑grant research university in Columbus, serving one of the nation’s largest student populations and a broad research enterprise. Industry partners engage through an integrated academic medical center for clinical translation, a campus‑adjacent innovation district for co‑located projects, and a statewide extension network that pilots solutions across Ohio. Corporate engagement provides a single front door for sponsored research, talent pipelines, and streamlined agreements. Research is supported by competitive federal funding from agencies such as NIH, NSF, DOE, USDA, DoD, and NASA. A dedicated technology transfer office and venture support help protect IP, license technologies, and launch startups.
delivered to your inbox.